Compstatin 40

N/A

Report date: 2025/10/30 20:00:05
NME

Base Information

Drug NameCompstatin 40
Drug Alias NameAMY-101
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionComplement C3 inhibitors
TargetsComplement C3
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Complement-Mediated DiseasesRespiratory Distress Syndrome, Adult +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAmyndas Pharmaceuticals Sa
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Complement-Mediated DiseasesRespiratory Distress Syndrome, Adult +[4] 

Other Information

ATC CodeN/A
Related LinksN/A